Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, Seike M, Takei Y, Kato K, Alves K, Burroughs M, Redman R, Pugatch DL, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Kumada H. Chayama K, et al. J Gastroenterol. 2018 Apr;53(4):557-565. doi: 10.1007/s00535-017-1391-5. Epub 2017 Sep 25. J Gastroenterol. 2018. PMID: 28948366 Free PMC article. Clinical Trial.
Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Suzuki F, Kumada H, Chayama K. Yatsuji H, et al. Among authors: chayama k. Antimicrob Agents Chemother. 2006 Nov;50(11):3867-74. doi: 10.1128/AAC.00239-06. Epub 2006 Sep 18. Antimicrob Agents Chemother. 2006. PMID: 16982790 Free PMC article.
Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy.
Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, Suzuki F, Kobayashi M, Chayama K, Imamura M, Yotsuyanagi H, Nakaoka S, Maki N, Kawata S, Kumada H, Iino S, Kiyosawa K. Matsumoto A, et al. Among authors: chayama k. Hepatol Res. 2007 Aug;37(8):661-6. doi: 10.1111/j.1872-034X.2007.00094.x. Hepatol Res. 2007. PMID: 17584261
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong S, et al. Among authors: chayama k. World J Gastroenterol. 2007 Oct 21;13(39):5188-95. doi: 10.3748/wjg.v13.i39.5188. World J Gastroenterol. 2007. PMID: 17876889 Free PMC article. Clinical Trial.
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong SC, et al. Among authors: chayama k. World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
1,568 results